[go: up one dir, main page]

MX9600503A - 10-aminoalifatil-dibenz(b,f)oxepinas anti-neurodegenerativamente activas. - Google Patents

10-aminoalifatil-dibenz(b,f)oxepinas anti-neurodegenerativamente activas.

Info

Publication number
MX9600503A
MX9600503A MX9600503A MX9600503A MX9600503A MX 9600503 A MX9600503 A MX 9600503A MX 9600503 A MX9600503 A MX 9600503A MX 9600503 A MX9600503 A MX 9600503A MX 9600503 A MX9600503 A MX 9600503A
Authority
MX
Mexico
Prior art keywords
oxepines
dibenz
formula
aminoaliphatil
divalent
Prior art date
Application number
MX9600503A
Other languages
English (en)
Inventor
Claudia Betschart
Kaspar Zimmermann
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of MX9600503A publication Critical patent/MX9600503A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/14—[b,f]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Epoxy Compounds (AREA)

Abstract

Las dibenz[b,f]oxepinas sustituidas por base, de la formula I: (Ver Formula) en donde alq es un radical alifático divalente, R es un grupo amino que está insustituido o mono- o di-sustituido por radicales alifáticos y/o aralifáticos monovalentes, o disustituido por radicales alifáticos divalentes, y R1, R2, R3, y R4 son cada uno, independientemente de los otros, hidrogeno, alquilo inferior, alcoxi inferior, halogeno, o trifluorometilo, y las sales farmacéuticamente aceptables de las mismas, se pueden utilizar como ingredientes activos antineurodegenerativos de medicamentos. La invencion se refiere también a compuestos novedosos de la formula I.
MX9600503A 1995-02-08 1996-02-06 10-aminoalifatil-dibenz(b,f)oxepinas anti-neurodegenerativamente activas. MX9600503A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH36795 1995-02-08

Publications (1)

Publication Number Publication Date
MX9600503A true MX9600503A (es) 1997-01-31

Family

ID=4185416

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9600503A MX9600503A (es) 1995-02-08 1996-02-06 10-aminoalifatil-dibenz(b,f)oxepinas anti-neurodegenerativamente activas.

Country Status (27)

Country Link
US (2) US5780500A (es)
EP (1) EP0726265B1 (es)
JP (2) JP3625559B2 (es)
KR (1) KR100485538B1 (es)
CN (1) CN1216052C (es)
AR (1) AR004474A1 (es)
AT (1) ATE203528T1 (es)
AU (1) AU715245B2 (es)
BR (1) BR9600339A (es)
CA (1) CA2168937C (es)
CY (1) CY2333B1 (es)
DE (1) DE59607332D1 (es)
DK (1) DK0726265T3 (es)
ES (1) ES2160790T3 (es)
FI (1) FI120400B (es)
GR (1) GR3036656T3 (es)
HU (1) HU229227B1 (es)
IL (1) IL117067A (es)
MX (1) MX9600503A (es)
MY (1) MY113427A (es)
NO (1) NO314356B1 (es)
NZ (1) NZ280940A (es)
PT (1) PT726265E (es)
RU (1) RU2160734C2 (es)
SA (1) SA01220313A (es)
TW (1) TW420672B (es)
ZA (1) ZA96960B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840749A (en) * 1989-08-25 1998-11-24 Hoechst Marion Roussel, Inc. N-hydroxy-dibenz b,e!oxepinalkylamines, N-hydroxy-dibenz b,e!oxepinalkanoic acid amides and related heterocyclic analogues
AR008371A1 (es) * 1996-05-30 2000-01-19 Novartis Ag Una sal de adicion con acido de una 10-aminoalifatil-dibenz[b,f],oxepina, su empleo; procedimiento para su elaboracion, una 10-aminoalifatil-dibenz[b,f]oxepina, una preparacion farmaceutica que contiene dicha sal o dicha oxepina y un procedimiento para el tratamiento de enfermedades neurodegenerativ
WO1997046549A1 (en) * 1996-06-05 1997-12-11 Novartis Ag Anti-neurodegeneratively effective xanthene derivatives
WO1998015647A1 (en) * 1996-10-08 1998-04-16 Novartis Ag Modulation of apoptosis
JP4777489B2 (ja) * 1997-03-31 2011-09-21 ザ チルドレンズ メディカル センター コーポレーション アポトーシス性酵素を不活性化するためのニトロシル化
BR0011529A (pt) 1999-06-03 2002-12-17 Nippon Suisan Kaisha Ltd Compostos de heterociclos fundidos tricìclicos, processo para preparar os mesmos e uso destes
WO2003057204A2 (en) * 2002-01-08 2003-07-17 Nordic Bioscience A/S Modulation of iamt (pimt or pcmt) in immune system
EP1589963A1 (en) * 2003-01-29 2005-11-02 Novartis AG Use of 10-aminoaliphatyl-dibenz b,f oxepines for the tr eatment of degenerative ocular disorders
AU2004290499C1 (en) * 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
US7906180B2 (en) * 2004-02-27 2011-03-15 Molecular Imprints, Inc. Composition for an etching mask comprising a silicon-containing material
EP1757284A1 (en) 2005-08-25 2007-02-28 Santhera Pharmaceuticals (Schweiz) AG Use of N-(dibenz(b,f)oxepin-10ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy
EP1842539A1 (en) 2006-04-05 2007-10-10 Santhera Pharmaceuticals (Schweiz) AG Use of N- (dibenz(b,f)oxepin-10-ylmethyl)N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency
KR20110087582A (ko) 2010-01-26 2011-08-03 삼성전자주식회사 식각액 조성물 및 이를 이용한 식각 방법
WO2014120885A1 (en) 2013-01-30 2014-08-07 The Johns Hopkins University Treatment of drug abuse by preventing gapdh nitrosylation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3100207A (en) * 1959-07-08 1963-08-06 Smith Kline French Lab 10-aminoalkylbenzo[b,f]thiepin and -dibenz[b,f]oxepin derivatives
NL124626C (es) * 1964-06-29
DE1493782B1 (de) * 1964-06-29 1969-12-11 Geigy Ag J R Basisch substituierte Dibenzo[b,f]-oxepine und deren nicht-toxische Salze
CH440318A (de) * 1964-11-03 1967-07-31 Geigy Ag J R Verfahren zur Herstellung von neuen Thiepin- und Oxepinderivaten
US3641056A (en) * 1970-01-06 1972-02-08 Ciba Geigy Corp 10-(aminomethyl)- and (aminoethyl)-dibenz (b f)oxepins
US3928383A (en) * 1973-06-08 1975-12-23 Hoffmann La Roche Propynylamine-substituted dibenzo{8 b,f{9 thiepins and dibenz{8 b,f{9 oxepins
IE62754B1 (en) * 1988-08-26 1995-02-22 Akzo Nv Tetracyclic antidepressants

Also Published As

Publication number Publication date
HUP9600272A3 (en) 2000-03-28
HUP9600272A2 (en) 1997-05-28
GR3036656T3 (en) 2001-12-31
AU715245B2 (en) 2000-01-20
JPH08259559A (ja) 1996-10-08
US5780501A (en) 1998-07-14
AU4330796A (en) 1996-08-15
HU9600272D0 (en) 1996-04-29
BR9600339A (pt) 1998-01-27
FI120400B (fi) 2009-10-15
EP0726265B1 (de) 2001-07-25
FI960529A (fi) 1996-08-09
JP2005008646A (ja) 2005-01-13
KR100485538B1 (ko) 2005-09-02
US5780500A (en) 1998-07-14
JP3625559B2 (ja) 2005-03-02
IL117067A0 (en) 1996-06-18
ZA96960B (en) 1996-08-08
RU2160734C2 (ru) 2000-12-20
TW420672B (en) 2001-02-01
DE59607332D1 (de) 2001-08-30
DK0726265T3 (da) 2001-10-22
EP0726265A1 (de) 1996-08-14
ES2160790T3 (es) 2001-11-16
NZ280940A (en) 1997-12-19
NO960499L (no) 1996-08-09
ATE203528T1 (de) 2001-08-15
PT726265E (pt) 2001-12-28
NO314356B1 (no) 2003-03-10
CA2168937C (en) 2009-10-20
FI960529A0 (fi) 1996-02-05
CA2168937A1 (en) 1996-08-09
AR004474A1 (es) 1998-12-16
CN1216052C (zh) 2005-08-24
CY2333B1 (en) 2004-02-06
SA01220313A (ar) 2005-12-03
HU229227B1 (en) 2013-09-30
IL117067A (en) 2000-08-13
KR960031452A (ko) 1996-09-17
CN1137039A (zh) 1996-12-04
NO960499D0 (no) 1996-02-07
MY113427A (en) 2002-02-28

Similar Documents

Publication Publication Date Title
MX9600503A (es) 10-aminoalifatil-dibenz(b,f)oxepinas anti-neurodegenerativamente activas.
FR2727682B1 (es)
TW427887B (en) Pharmaceutical composition comprising a benzimidazole derivative for treating viral infections
MY114679A (en) Aroyl-piperidine derivatives
TR200102957T2 (tr) Sitalopram hazırlanması için metod.
GR82135B (es)
GB9408185D0 (en) New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
MXPA02004448A (es) Derivados de imidazopiridina como inhibidores de la fosfodiesterasa vii.
PH20072A (en) Anti-hypertensive 1-substituted spiro-(piperidine-oxobenzoxazine)s
MY103214A (en) Antihypercholesterolemic tetrazole compounds
BG104569A (en) Substituted 2-benzylamino-2-phenyl-acetamide compounds
MY129935A (en) Dihydropyridine derivatives useful in antitumor therapy
AU2001269540A1 (en) Serotonin reuptake inhibitors
MY102081A (en) 1,3-oxazolidine-2-one derivatives and processes for their preparation
MY102921A (en) Amino-alcohol derivatives and processes for their preparation.
AU6063398A (en) Pyrrolidine derivative, anti-ulcer drug, and antibacterial drug
AU6063498A (en) Alkylenediamine derivative, anti-ulcer drug, and antibacterial drug
EP0335979A4 (en) Thienopyrimidine derivatives
TW230771B (es)
SE7412163L (es)
WO1987007609A1 (en) 1,1,2-triaryl-1-butene derivatives
KR880001604A (ko) 1-치환된 3-아릴-7-클로로-3,4-디하이드로(2h)-아크리돈 n-옥사이드, 그들의 제조방법, 및 약제 및 사료첨가제로서의 그들의 용도
ES8801657A1 (es) Un procedimiento para la preparacion de un compuesto de quinazolina
NZ291855A (en) Bridged azabicyclo-piperazin-1-yl-2-phenyl-butan-1-one derivatives as 5-ht1a antagonists
ES8405020A1 (es) Un procedimiento para la preparacion de derivados de fosfolipidos.